Recalcitrant SIBO cases often share a familiar pattern. Antimicrobial or prescription treatment clears the breath test, symptoms may improve for a period, and then the pattern relapses. Or symptoms improve slightly but we never have resolution of the symptoms or a breath test that fully clears. When this cycle repeats despite appropriately dosed and sequenced treatment, the question shifts from which antimicrobial to use next to why is this so persistent and difficult to treat. There are a number of possible reasons why SIBO remains hard to treat but I want to discuss one of them in particular. Small intestinal motility and an impaired migrating motor complex (MMC).
This case follows a patient with a common presentation I see in practice. A mixed SIBO case positive for both intestinal methanogen overgrowth (IMO) and hydrogen (H2) dominant SIBO in a patient with a long history of IBS symptoms, histamine intolerance and a history of foodborne illness.
Patient Presentation
The patient is a 38-year-old female with a several-year history of alternating constipation and diarrhea, consistent with IBS-M. She reports bloating that worsens through the day, intermittent abdominal pain, and fatigue that correlates with flares. Her digestive symptoms began gradually in her early 30s, roughly 6-12 months after two documented episodes of food poisoning experienced during international travel, both associated with several days of acute diarrheal illness that resolved without long-term follow-up at the time.
She had completed two prior rounds of SIBO treatment (herbal antimicrobials and Rifaximin with Neomycin) through a previous provider, each producing partial symptom relief that did not hold. Gas levels on repeat breath testing remained persistently elevated despite treatment, and her bowel pattern continued to alternate rather than settle into a predictable presentation. This presentation with persistently high gas levels despite multiple treatments and a documented foodborne illness history, is precisely the profile that warrants investigation beyond another round of the same treatment.
Initial Testing and Findings
A baseline SIBO breath test was ordered to characterize her gas pattern before adjusting treatment.
Table 1. SIBO Breath Test (Genova Diagnostics, 3-Hour Lactulose)
| Sample | Time (min) | H2 (ppm) | CH4 (ppm) |
|---|---|---|---|
| S1 (baseline) | 0 | 8 | 4 |
| S2 | 20 | 14 | 6 |
| S3 | 40 | 22 | 9 |
| S4 | 60 | 31 | 12 |
| S5 | 90 | 34 | 14 |
| S6 | 120 | 29 | 16 |
| S7 | 150 | 24 | 15 |
| S8 | 180 | 19 | 13 |
Her hydrogen rose 26 ppm over baseline by 90 minutes, well above the 20 ppm threshold for a positive hydrogen result, and her methane peaked at 16 ppm, above the 10 ppm threshold used to identify intestinal methanogen overgrowth (Rezaie et al. 2017). This mixed pattern is clinically important to recognize on its own terms. While IMO is associated with constipation and hydrogen more with diarrhea as general tendencies, these are not fixed rules and we often see IBS-M type presentations in these patients. So, while the testing and gas dominance type can be informative, you also want to pay attention to the symptoms and patterns of the patient.
The Clinical Inflection Point: Why ibs-smart Was Ordered
Three criteria converged to prompt antibody testing: a recalcitrant treatment course, persistently high gas levels despite treatment, and a documented history of foodborne illness correlating with international travel. This combination is the clearest clinical signal to investigate a post-infectious, autoimmune driver of her dysmotility rather than continuing to treat the overgrowth in isolation. Also, a clinical reminder that a thorough health history asking about travel and food poisoning history is important.
The mechanism linking her history to her current presentation is well described. Common foodborne pathogens, including Campylobacter, Shigella, Salmonella, and certain strains of E. coli, release cytolethal distending toxin B (CdtB) during acute infection. The immune response generates anti-CdtB antibodies within weeks of the infection. Because CdtB shares structural similarity with vinculin, a cytoskeletal protein expressed in the interstitial cells of Cajal (ICC) and the myenteric plexus, the immune system can begin cross-reacting against vinculin through molecular mimicry, typically months after the initial infection (Sharabi et al. 2025). Since vinculin is central to the pacemaker function of the ICC and the coordination of the migrating motor complex (MMC), sustained anti-vinculin antibody activity is associated with impaired gut motility, providing a plausible mechanistic link between a remote infection and a persistent small intestinal environment favorable to bacterial overgrowth.
Table 2. ibs-smart (Gemelli Biotech, Second-Generation Assay)
| Antibody Detected | Patient Value (OD) | Reference Interval | Antibody Level |
|---|---|---|---|
| Anti-CdtB Ab | 1.9 | 0.00–1.56 | Elevated |
| Anti-Vinculin Ab | 2.4 | 0.00–1.60 | Elevated |
Both markers returned elevated. Per the clinical scenario framework developed from this biomarker’s use, a pattern of elevated anti-CdtB with elevated anti-vinculin suggests a recent infection (high anti-CdtB) with a past infection, now compounded by an established autoimmune component to her IBS. Given her history of two documented infections years apart, this composite pattern is likely consistent with cumulative post-infectious antibody activity rather than a single isolated event.
Clinical pearl: A positive ibs-smart result does not replace the SIBO workup. It reframes it. The finding shifts the treatment focus from eradication alone toward parallel support of small intestinal motility, since eradicating bacteria without addressing the underlying MMC impairment sets the stage for the same relapse pattern that brought the patient in.
Treatment Reasoning and Sequencing
Her mixed IMO and H2-dominant pattern warranted a combined approach targeting both hydrogen-producing bacteria and methanogens concurrently, rather than treating one gas type and reassessing before addressing the other. Given the antibody findings, motility support was introduced as a first step before repeat treatment rather than an afterthought reserved for relapse.
Prokinetic support works through one of two general mechanisms: inhibiting dopamine, which itself inhibits motility, or stimulating acetylcholine, which promotes it. The specific agent selection depends on patient tolerance, bowel pattern, and prior response, and is intentionally not detailed here at the protocol level but is covered in our Practitioner Certification and Fellowship Program. What matters clinically is the sequencing principle: in a patient with a positive ibs-smart result, motility support is not an optional add-on for symptom comfort. It addresses a documented mechanism contributing to her recurrence risk. I typically will introduce a prokinetic 4-6 weeks before restarting treatment, to help support the MMC and motility of the upper GI tract before adding in another treatment.
Patient counseling also became part of the treatment plan. Given her history of two prior infections and now-elevated antibody levels, she was counseled on the potential for future foodborne illness, particularly with continued international travel, to further elevate her antibody burden and prolong her dysmotility. This counseling does not carry a validated preventive intervention behind it. The most defensible counseling point remains prevention of the initiating infection itself.
Retesting and Outcome
This patient received prokinetic support for 4-6 weeks before initiating a combination herbal antimicrobial + prescription protocol for SIBO. The patient completed 12 weeks of treatment for SIBO and remained on the prokinetic. SIBO breath testing was repeated after completion of SIBO treatment, with antimicrobials held for the standard two to four week window beforehand. Her repeat breath test showed meaningful reduction in both hydrogen and methane peaks, and her bowel pattern became more predictable, favoring formed stool with occasional loose days rather than the prior unpredictable alternation, as well as improved tolerance of food.
The ibs-smart panel was not repeated on the same timeline as the breath test. Antibody levels do not track antimicrobial treatment the way gas production does. Unlike a breath test, which can normalize within weeks of successful eradication, anti-vinculin antibody levels behave more like a sustained immune response and typically require twelve months or longer to show meaningful change, if they change at all (Pimentel, SIBO and IBS Live Q&A 2026). Her ibs-smart panel was repeated at fourteen months.
Table 3. ibs-smart Retest, 14 Months Later
| Antibody Detected | Initial (OD) | Retest (OD) | Change |
|---|---|---|---|
| Anti-CdtB Ab | 1.9 | 1.6 | Modest decline, still elevated |
| Anti-Vinculin Ab | 2.4 | 2.1 | Modest decline, still elevated |
This pattern is consistent with what the most recent data on antibody kinetics shows. In a 417-patient retrospective chart review, anti-vinculin normalized in only 12 of 20 patients with initially elevated levels who had repeat testing, with a mean time to normalization of 23.7 months, and normalization correlated significantly with symptom improvement (p = 0.020). Notably, eight patients in that same cohort saw their anti-vinculin levels rise further between tests, and of those, only one reported symptom improvement (Sharabi et al. 2025). Antibody-depleting therapies such as IVIG and plasmapheresis produced higher rates of normalization than usual management in that cohort, but these are not accessible or appropriate interventions for the majority of SIBO and IBS patients seen in practice. There is more research and studies needing to be done in this area.
Clinical pearl: This patient’s antibody levels declined but did not normalize at fourteen months, while her symptoms and breath test improved meaningfully. This should not be interpreted as treatment failure. It reflects the current reality that there is no established therapy that reliably clears anti-CdtB or anti-vinculin antibodies on a clinically useful timeline. Managing the downstream motility consequence remains the practical target while the field continues to develop antibody-directed treatments. This patient stayed on prokinetic therapy ongoing and we continued to work on supporting digestion and prevention of SIBO recurrence.
Clinical Takeaways
Consider ibs-smart testing in any patient with recalcitrant SIBO or IBS, persistently elevated gas levels despite appropriate treatment, or a history of foodborne illness that correlates with symptom onset, even when that history is remote. A positive result should shift the treatment plan toward parallel motility support rather than repeated rounds of antimicrobial treatment alone. Retest the antibody panel on a much longer interval than the breath test, generally at twelve months or beyond, and set expectations accordingly: antibody normalization is inconsistent, often incomplete, and not currently a treatment target with a reliable intervention behind it. Symptom and breath test improvement remain the most actionable markers of progress in the interim. Test, don’t guess, applies here as much as it does to gas typing itself.
Ready to build this kind of case-based clinical reasoning into your own practice? The Adapt Practitioner Certification and Fellowship Program teaches the full diagnostic and treatment sequencing behind cases like this one, from advanced lab interpretation to protocol design grounded in current research. Put your deposit down now!
Resources
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017.
Sharabi E, Busam JA, Mathur K, et al. Tracking Anti-cytolethal Distending Toxin B and Anti-vinculin Over Time and Their Roles in Symptoms. Dig Dis Sci. 2025;70(6):2016-2020.
Pimentel M. SIBO and IBS Updates, Live Q&A. SIBO Info, 2026.
